NQO2 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant NQO2.
|Application ||WB, E|
|Calculated MW||25919 Da|
|Other Names||Ribosyldihydronicotinamide dehydrogenase [quinone], NRH dehydrogenase [quinone] 2, NRH:quinone oxidoreductase 2, Quinone reductase 2, QR2, NQO2, NMOR2|
|Target/Specificity||NQO2 (AAH06096.1, 1 a.a. ~ 231 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||NQO2 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NQO2 (EC 184.108.40.206) is a flavoprotein that catalyzes the 2-electron reduction of various quinones, redox dyes, and the vitamin K menadione. NQO2 predominantly uses dihydronicotinamide riboside (NRH) as the electron donor (summary by Wu et al., 1997 [PubMed 9367528]).
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.Association of disease-predisposition polymorphisms of the melatonin receptors and sunshine duration in the global human populations. Ji LD, et al. J Pineal Res, 2010 Mar. PMID 20050988.Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Choi JY, et al. Clin Cancer Res, 2009 Aug 15. PMID 19671875.Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2. Yu KD, et al. Breast Cancer Res Treat, 2009 Dec. PMID 19495956.Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Yu KD, et al. Hum Mol Genet, 2009 Jul 1. PMID 19351655.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.